Lumexa Imaging Holdings, Inc. (LMRI) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analysts are broadly bullish: Lumexa Imaging has a consensus “Buy” rating from six firms, with three buys, two strong buys and one sell. The average 12-month price target is $16.40, above the stock’s recent $10.89 price.
• Recent earnings exceeded expectations: The company reported quarterly EPS of $0.20 versus the $0.03 consensus estimate, on revenue of $264.16 million. Management’s fiscal 2026 EPS guidance is $0.71–$0.77.
• Institutional interest has increased: Several hedge funds and investment firms initiated or expanded positions, including Squarepoint Ops, which raised its stake by more than 500%, and Readystate Asset Management, which increased its holdings by 11.5%.

Shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Get Free Report) have been given a consensus rating of "Buy" by the six ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $16.40.

Several research analysts have recently commented on the company. UBS Group reissued a "strong-buy" rating on shares of Lumexa Imaging in a research report on Monday, September 28th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Lumexa Imaging in a report on Tuesday, September 22nd. KeyCorp initiated coverage on Lumexa Imaging in a report on Thursday, September 24th. They set an "overweight" rating and a $18.00 price objective for the company. Raymond James Financial set a $17.00 target price on Lumexa Imaging in a research note on Monday, September 28th. Finally, Barclays upped their target price on Lumexa Imaging from $9.00 to $13.00 and gave the company an "overweight" rating in a research report on Friday, August 28th.

Lumexa Imaging Price Performance

Shares of LMRI opened at $10.89 on Friday. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.44 and a current ratio of 1.44. The company has a 50 day moving average price of $11.14 and a 200-day moving average price of $10.33. Lumexa Imaging has a fifty-two week low of $6.45 and a fifty-two week high of $19.45. The stock has a market capitalization of $1.05 billion and a PE ratio of -22.22.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.17. The business had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities analysts predict that Lumexa Imaging will post 0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lumexa Imaging

Several hedge funds have recently modified their holdings of the stock. State of Alaska Department of Revenue acquired a new stake in Lumexa Imaging in the 3rd quarter worth approximately $46,000. Squarepoint Ops LLC increased its stake in Lumexa Imaging by 506.9% during the 2nd quarter. Squarepoint Ops LLC now owns 79,934 shares of the company's stock valued at $902,000 after purchasing an additional 66,763 shares in the last quarter. Readystate Asset Management LP increased its stake in Lumexa Imaging by 11.5% during the 2nd quarter. Readystate Asset Management LP now owns 250,533 shares of the company's stock valued at $2,826,000 after purchasing an additional 25,778 shares in the last quarter. AXQ Capital LP acquired a new position in Lumexa Imaging during the 2nd quarter valued at approximately $128,000. Finally, Bank of America Corp DE purchased a new position in shares of Lumexa Imaging in the second quarter worth $200,000.

About Lumexa Imaging

Lumexa Imaging is a U.S.-based provider of outpatient diagnostic imaging and radiology services. The company operates imaging centers and offers services designed to support physicians, hospitals, health systems and patients in the diagnosis and monitoring of medical conditions.

Its service portfolio includes advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound and X-ray. Lumexa also provides radiology-related services, including image interpretation and support for referring healthcare providers, through fixed-site and mobile imaging operations.

The company serves communities across the United States through its network of outpatient facilities and healthcare partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.